Linperlisib – Medxy AI

Linperlisib Potentiates MUC1-Tn CAR T Cell Therapy by Suppressing the EGR1/DUSP2 Axis to Combat T-Cell Acute Lymphoblastic Leukemia

By MedXY 07/06/2026

This study highlights how linperlisib, a PI3Kδ inhibitor, enhances MUC1-Tn CAR T cell efficacy in T-ALL by preventing T cell exhaustion via suppression of the EGR1/DUSP2 pathway, improving anti-leukemic activity and persistence.

$Innovative All-Oral Therapy: Linperlisib Plus Chidamide Shows Promise in Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Clinical Updates Hematology-Oncology news Specialties

Innovative All-Oral Therapy: Linperlisib Plus Chidamide Shows Promise in Relapsed or Refractory Cutaneous T-Cell Lymphoma

By MedXY 09/03/2025

A phase 1 trial of linperlisib combined with chidamide demonstrated manageable safety and notable efficacy in relapsed/refractory CTCL, offering a potential new oral treatment option for advanced disease, especially mycosis fungoides.

$Linperlisib Plus Chidamide: A Promising Oral Therapy for Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Clinical Updates Hematology-Oncology Specialties

Linperlisib Plus Chidamide: A Promising Oral Therapy for Relapsed or Refractory Cutaneous T-Cell Lymphoma

By MedXY 08/23/2025

This phase 1 trial demonstrates that linperlisib combined with chidamide offers manageable safety and noteworthy efficacy in relapsed or refractory cutaneous T-cell lymphoma, providing a potential new all-oral therapeutic option for advanced disease.